Manhattan West Asset Management LLC Buys New Shares in IQVIA Holdings Inc. $IQV

Manhattan West Asset Management LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 16,574 shares of the medical research company’s stock, valued at approximately $3,202,000.

A number of other institutional investors have also bought and sold shares of IQV. Calamos Advisors LLC lifted its holdings in IQVIA by 268.1% in the 4th quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after purchasing an additional 137,441 shares in the last quarter. Concurrent Investment Advisors LLC grew its holdings in IQVIA by 36.0% during the 4th quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock valued at $2,693,000 after buying an additional 3,161 shares in the last quarter. Nippon Life Global Investors Americas Inc. raised its position in shares of IQVIA by 36.6% during the fourth quarter. Nippon Life Global Investors Americas Inc. now owns 79,400 shares of the medical research company’s stock valued at $17,898,000 after buying an additional 21,270 shares during the last quarter. BlackRock Inc. purchased a new position in shares of IQVIA in the second quarter worth $2,811,292,000. Finally, Munich Reinsurance Co Stock Corp in Munich purchased a new position in shares of IQVIA in the fourth quarter worth $3,444,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $260.17 on Friday. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $260.40. The firm has a market capitalization of $42.82 billion, a P/E ratio of 32.28, a price-to-earnings-growth ratio of 2.17 and a beta of 1.18. The company has a fifty day simple moving average of $213.32 and a two-hundred day simple moving average of $187.52. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 12,913 shares of company stock valued at $3,098,793. Insiders own 1.70% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on IQV shares. Royal Bank Of Canada lifted their price target on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. increased their price objective on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Robert W. Baird raised their price target on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.